Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $372000.0.

  • Protalix BioTherapeutics' Depreciation & Amortization (CF) rose 1306.99% to $372000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 928.79%. This contributed to the annual value of $1.3 million for FY2024, which is 866.67% up from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Depreciation & Amortization (CF) stood at $372000.0, which was up 1306.99% from $360000.0 recorded in Q2 2025.
  • In the past 5 years, Protalix BioTherapeutics' Depreciation & Amortization (CF) ranged from a high of $372000.0 in Q3 2025 and a low of $259000.0 during Q4 2021
  • For the 5-year period, Protalix BioTherapeutics' Depreciation & Amortization (CF) averaged around $305263.2, with its median value being $293000.0 (2023).
  • In the last 5 years, Protalix BioTherapeutics' Depreciation & Amortization (CF) plummeted by 2393.62% in 2021 and then skyrocketed by 1500.0% in 2024.
  • Protalix BioTherapeutics' Depreciation & Amortization (CF) (Quarter) stood at $259000.0 in 2021, then increased by 11.58% to $289000.0 in 2022, then rose by 11.42% to $322000.0 in 2023, then increased by 3.73% to $334000.0 in 2024, then grew by 11.38% to $372000.0 in 2025.
  • Its last three reported values are $372000.0 in Q3 2025, $360000.0 for Q2 2025, and $346000.0 during Q1 2025.